Cannabis drinks have attracted a lot of hype based on their potential to bring new consumers into the industry, but early iterations of these drinks haven’t been runaway success stories.

There are a variety of factors at play, but according to the data available, one key issue may simply be a lack of interest from the existing consumer base.

In an interview with the Investing News Network (INN), Michelle Sundquist, director of innovation product design with SoRSE Technology, a Seattle-based CBD product developer, talked about the development of these drinks and their future.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Sundquist spent 20 years with Starbucks (NASDAQ:SBUX) in a variety of roles, but primarily focused on product development, alongside research on consumer interest trends for new beverages.

The beverage expert said the hesitation seen from consumers is to be expected as purchasing tendencies and understanding of these beverages settle in.

“They may not have trust in the ingredients, they might not have trust in the format,” Sundquist said.

“There’s a little confusion as to, ‘If it’s in my beverage, how much should I have? Is it real? How much CBD is really in it? And does it come from a reputable company?'”

In the end, attracting consumers will require proven marketing and beverage design tactics, she said.

“People might be a little bit hesitant to buy it because it’s not calling out to them as something that’s made for them,” Sundquist explained. “So a lot of it comes down to figuring out who your consumer is and figuring out how they are going to get your product.”

What about brand new consumers? Sundquist told INN if a consumer walks into a store not knowing about the products available, they will likely gravitate towards something that looks familiar to them.

“It’s not enough just to have a solid product if the flavors are not right, if the timing is not right, if the place isn’t right — then you’re going to have a really difficult time,” she said.

Canada poised to deliver modern drinks market

In Canada, Canopy Growth (NYSE:CGC,TSX:WEED) has relentlessly pursued consumers who may be open to making cannabis drinks their preferred delivery method.

“Based on our research, 17 percent of Canadian adults who currently don’t consume cannabis say they intend to use recreational cannabis … We see a significant opportunity to recruit these intended consumers through products like our drinks,” CEO David Klein said this summer, according to a report from Marijuana Business Daily.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

In its most recent quarterly report, Canopy Growth, which has a partnership with Constellation Brands (NYSE:STZ), notes that it sold just over a million cans of its drinks during the period.

What’s more, Klein told Yahoo Finance the company’s drinks represented 74 percent of the total beverages sold in Canada over a year-to-date period as of mid-August.

However, the promise hasn’t reached its full potential, and currently vape pen products dominate the Cannabis 2.0 portion of products in Canada. Recreational products became legal in October 2018, but ingestible and vaporized products didn’t go up for sale until a year later.

Cannabis giant Canopy Growth will also soon be facing increasing competition as the love child corporation from cannabis producer HEXO (NYSE:HEXO,TSX:HEXO) and Molson Coors Beverage (NYSE:TAP,TSX:TAP) finally launches its drinks into the market.

The offerings from Canopy Growth and HEXO have attracted increased attention given the companies’ relationships with major beverage companies.

CBD plays a key role for wellness consumers

CBD is a strong mainstream element of the cannabis market, and when it comes to beverages Sundquist said CBD drinks tend to tap into the idea of wellness — an industry that reached US$4.5 trillion in 2018.

Consumers’ desire to know more about ingredients and the wellness aspect associated with a wide range of products are directly tied to the rise of CBD wellness products, Sundquist said.

An instant connection between CBD and the wellness segment, according to the beverage expert, is sparkling water products.

“People want to drink sparkling water because it hydrates, it has no calories, they don’t have to worry about clean ingredient statements because it’s just water,” Sundquist said. “Adding CBD sparkling water is an easy connection into something that people can easily incorporate into their lives.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less